CLAIMS

1. A polypeptide having an amino acid sequence set forth in the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53 and SEQ ID NO: 54.

2. The polypeptide according to claim 1, wherein the polypeptide has a sequence set forth in any one of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8.

3. The polypeptide according to claim 1, wherein the polypeptide sequence is set forth in SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 27.

4. The polypeptide according to claim 1, wherein the polypeptide is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14.

5. The polypeptide according to claim 1, wherein the polypeptide is selected from the group consisting of polypeptide sequences set forth in SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24.

6. The polypeptide according to claim 1, wherein the polypeptide is selected from the

group consisting of polypeptide sequences set forth in SEQ ID NO: 7, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 25, and SEQ ID NO: 26.

7. The polypeptide according to claim 1, wherein the polypeptide is selected from the group consisting of polypeptide sequences set forth in SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53 and SEQ ID NO: 54.

8. Use of the polypeptide according to claim 1 in the manufacture of a medicament for prevention and/or treatment of a fibrosis disease.

9. The use according to claim 8, wherein the fibrosis disease is a disease caused by excessive activation of TGF-β cytokine and a signaling pathway thereof, wherein the disease is selected from the group consisting of rheumatoid arthritis, pulmonary fibrosis, hepatic fibrosis, cirrhosis, renal fibrosis, myelofibrosis, myocardial fibrosis, sarcoidosis, systemic sclerosis, keloids, burn-induced hypertrophic scars, proliferative retinopathy, glaucoma, cataract, posterior capsule opacification, angioplasty, vascular restenosis after vascular surgery or vascular injury, cystic fibrosis, and Marfan syndrome.

10. The use according to claim 8, wherein the polypeptide can be used as a single active ingredient, in combination with each other, or in combination with other drugs as an active ingredient.

11. The use according to claim 8, wherein a pharmaceutically acceptable carrier is also used with the polypeptide, wherein the pharmaceutically acceptable carrier is selected from the group consisting of diluent, filler, excipient, binder, wetting agent, disintegrant,

effervescent, surfactant, absorption enhancer, lubricant, adsorption carrier, sustained release microsphere, implant agent, in situ forming microparticle, liposome, micro-emulsion, in situ hydrogel, nanoparticle, protease inhibitor, biological adhesive, fusion protein, antibody, and polypeptide.

12. The use according to claim 8, wherein the polypeptide is in a dosage form selected from the group consisting of tablet, injection, capsule, granule, ophthalmic preparation, inhalation preparation, ointment, cream, spray, aerosol, gel, powder, paint, implant, and lotion.

13. The use according to claim 9, wherein the polypeptide is administered by a route of administration selected from the group consisting of oral administration, pulmonary administration, nasal administration, transdermal administration, ocular administration, intravenous drip, intraperitoneal injection, subcutaneous injection, and intramuscular injection.

14. The polypeptide according to any one of claims 1 to 7 for use as a medicament.